Growth signals IQVIA demonstrates strong revenue performance with recent quarterly results beating expectations, and notable leadership transitions in 2026 suggesting ongoing strategic evolution that may open opportunities for new partnerships, services, or expanded analytics engagements.

AI powered The launch of IQVIA.ai at NVIDIA GTC positions the company at the forefront of AI-enabled clinical research, analytics, and automation, indicating potential sales angles around AI driven insights, workflows, and efficiency improvements for pharma customers.

Strategic collaborations Ongoing and renewed partnerships with industry players and patient advocacy groups, including NBTS and Kexing Biopharm, signal a receptiveness to collaborative programs and managed services that could be extended to other life sciences verticals and regions.

Global market insights IQVIA Global Market Insights specializes in measuring and sizing opportunities across the drug lifecycle, offering entry points for selling enhanced market access analytics, portfolio optimization, and portfolio prioritization services to manufacturers expanding global footprint.

Leadership exits Recent executive movements in leadership roles related to renal and technology domains may create openings for advisory, program governance, or transitional support services as the company redefines strategic focus areas.